Thank you for sharing!

Your article was successfully shared with the contacts you provided.

AstraZeneca called Prilosec “the Purple Pill,” but the heartburn medication was more than just a colorful tablet. Considered one of the most successful prescription drugs of all time, Prilosec global sales peaked in 2000 at $6 billion. By then AstraZeneca was already planning for patent expiration in 2001. That year, the company launched Nexium, another heartburn medication that AstraZeneca markets as the new Purple Pill. Stripped of its colorful moniker, Prilosec is now sold over-the-counter for less than $1 per pill; Nexium generally costs three times as much. Last year it took in $5.7 billion in global sales.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.